Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
250 results about "Cis-platinum" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cisplatin, cis-platinum. a platinum-containing complex used as an antineoplastic agent whose main mode of action resembles that of alkylating agents—production of cross-links between the two strands of DNA in the double helix so that DNA cannot be replicated and the cells cannot divide. Saunders Comprehensive Veterinary Dictionary, 3 ed.
Tetravalent platinum complex with bioactive group and preparation method of tetravalent platinum complex
The invention discloses a tetravalent platinum complex with a bioactive group and a preparation method of the tetravalent platinum complex. The tetravalent platinum complex is a platinum (IV) complex and has the structure shown in the formula II (please see the formula in the description), wherein in the formula II, Y is OH or Cl, and Bio represents the bioactive group. The platinum (IV) complex is prepared according to the equation in the formula III (please see the formula in the description), wherein in the formula III, Y is OH or Cl, Bio-OH represents a compound with bioactivity, TBTU represents a coupling agent O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, TEA represents a catalyst triethylamine, DMF represents solvent N,N-dimethyl formamide, and DMSO represents solvent dimethylsulfoxide. Cis-platinum is adopted for the bottom face of an octahedron, a small-molecular targeted or medicine active group is introduced to one axial position, a hydroxyl group or helium atom is introduced into another axial position, and the anti-tumor tetravalent platinum complex overcoming cisplatin resistance is provided, so the high-efficiency and low-toxin platinum (IV) complex is obtained.
Owner:SOUTHEAST UNIV
Nano micelle of biodegradable macromolecular-bonding Pt(IV) anti-cancer medicament and preparation method thereof
ActiveCN102120036AReduce toxic and side effectsNo toxicityHeavy metal active ingredientsPharmaceutical non-active ingredientsCarboplatinPolyester
The invention relates to a nano micelle of a biodegradable macromolecular-bonding Pt(IV) anti-cancer medicament and a preparation method thereof. The structural formula of the anti-cancer medicament is defined in the specification, wherein the biodegradable macromolecule is tri-block copolymer, namely polyethylene glycol-b-polyester-b-polylysine; and tetravalency platinum coordination compound Pt(IV) is connected with a side amino on the block of polylysine on a macromolecular carrier through alpha, omega-polyethylene glycol. The carrier is non-toxic and is water-soluble, thus being convenient for reacting with the platinum(IV) coordination compound in water phase; a nano micelle form can be formed through self assembly; a platinum(IV) coordination compound is reduced to platinum(II), namely, cis-platinum, Carboplatin or Oxaliplatin, and the anti-cancer effect is known; the synthesis of the nano micelle is easy; the reduction potential of platinum(IV) is low, so that the platinum(IV) can be rapidly reduced to platinum(II) in cancer cells to take treatment effect; and the platinum(IV) is connected to the side chain of the macromolecule rather than the end of a chain, a macromolecular chain can be connected with multiple platinum(IV)s, and the content of platinum can be as high as 10-20%.
Owner:吉林市博禹祥实工贸有限公司
Furazan derivative of coumarin parent nucleus and antineoplastic activity
ActiveCN105153142ANovel structureInhibitory activityOrganic active ingredientsOrganic chemistryHigh concentrationCancer cell
Owner:FUDAN UNIV
Biodegradable high-polymer bonded photoactive Pt (IV) anticancer medicament micelle and preparation method thereof
ActiveCN102416181ASignificant photoactivityFast releasePowder deliveryPharmaceutical non-active ingredientsChemical synthesisPolyester
The invention provides a biodegradable high-polymer bonded photoactive Pt (IV) anticancer medicament micelle and a preparation method thereof, which relate to the field of novel chemical synthesis medicaments and preparations thereof and are used for solving the problem that a high-polymer-platinum (IV) bonded medicament does not have optical activity in the prior art. In an anticancer medicament, ethylene glycol-b-polyester-b-polylysine serving as a biodegradable triblock copolymer or polyethylene glycol-b-poly(ester-co-carbonic ester) serving as a diblock copolymer is taken as a carrier polymer, and Pt (IV) is a photoactive tetravalent platinum composition coordinated with dihydroxyl in the axial direction. The invention further provides a preparation method of the biodegradable high-polymer bonded photoactive Pt (IV) anticancer medicament micelle. The anticancer medicament prepared with the method has remarkable optical activity; under the irradiation of UV (Ultraviolet) of 365 nanometers, Pt (IV) is reduced into Pt (II); a cis-platinum or oxaliplatin antitumor active part is contained; and the mass content of platinum can be up to 10-20 percent.
Owner:吉林市博禹祥实工贸有限公司
Application of dimethyldiguanide in preparation of medicaments for preventing or treating hepatocellular carcinoma
The invention relates to the technical field of medicaments. Dimethyldiguanide belongs to a biguanides oral hypoglycemic medicament and is widely applied to pharmaceutical therapy of type 2 diabetes. The invention aims at providing a novel application of the dimethyldiguanide and particularly an application of the dimethyldiguanide in preparation of medicaments for preventing or treating the hepatocellular carcinoma. According to the application disclosed by the invention, the restriction effect of the dimethyldiguanide on the hepatocellular carcinoma is found by research from two aspects, namely, cell culture in vitro and animal experiment in vivo. Experiments find that the dimethyldiguanide has the capabilities of restricting proliferation and clone formation of a hepatocellular carcinoma cell line and causing the cell cycle arrest and apoptosis increase of the hepatocellular carcinoma cell line, and also has the capability of enhancing the hepatocellular carcinoma resisting effect of chemotherapeutics when combined with the chemotherapeutics, such as cis-platinum, doxorubicin and the like. The invention provides the novel application of the dimethyldiguanide and also provides a novel concept for prevention and treatment of the hepatocellular carcinoma.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Application of miltirone in preparation of antitumor drugs
ActiveCN103845314ASynergisticObvious cytotoxic effectOrganic active ingredientsHeavy metal active ingredientsSalvia miltiorrhizaCytotoxic drug
The invention discloses an application of miltirone in preparation of antitumor drugs. The miltirone has a structure of formula I; the miltirone serves as an inhibitor of STAT3 (Signal Transducer and Activator of Transcription 3) and is capable of inhibiting growth and proliferation of tumor cells which are abnormally activated by STAT3 so as to cause the apoptosis of the tumor cells and also capable of improving sensibility of cytotoxic drugs and inhibiting formation of tumor vessels. The miltirone with the structure of formula I can inhibit STAT3 kinase Tyr705 phosphorylation level to achieve the functions of accelerating the apoptosis of the tumor cells, improving the sensibility of chemotherapy drugs and inhibiting formation of new vessels; and the proliferation of tumor cells can be significantly inhibited due to the combined combination of the miltirone with low toxicity or non-toxic concentration and adriacin doxorubicin with low toxicity or non-toxic concentration and the combined application of the miltirone and cis-platinum with low toxicity or non-toxic concentration. The functions of the miltirone with the structure of formula I have positive significance to prevention and treatment of tumors.
Owner:ZHEJIANG PROVINCIAL HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Preparation method and application of multifunctional membrane-controlled targeting nano-carrier integrating tracing and targeted drug delivery effects
ActiveCN107865972ARich in mesoporesRich surfaceOrganic active ingredientsPowder deliveryFluorescenceImatinib
The invention belongs to the technical fields of preparation and applications of nano-carriers, and in particular discloses a preparation method and an application of a multifunctional membrane-controlled targeting nano-carrier integrating tracing and targeted drug delivery effects. With nano mesoporous silica (MSN) as a drug 'warehouse', a positively charged high molecular material and a negatively charged high molecular material as preparation materials of a gating membrane, and adriamycin (DOX), cis-platinum, imatinib, taxol and the like as model anti-cancer drugs, research contents mainlyinclude optimization and improvement of natural materials, construction and process optimization of the gating membrane, structural characterization of a nano complex, drug release kinetic characteristics of drug molecules under the control of the gating membrane, and the like. Meanwhile, in the combination with the tracing imaging function of a fluorescent quantum dot, drug delivery behaviors andanti-tumor effectiveness of the membrane-controlled nano drug delivery system undergo preliminary evaluation through in-vitro experiments. Based upon research results, references are provided for thedesign and preparation of the novel membrane-controlled nano drug delivery system.
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
Anti-cancer medicinal aspirin platinum complex and preparation method thereof
InactiveCN102942594AInhibit apoptosisInhibition of replicationGroup 8/9/10/18 element organic compoundsAntineoplastic agentsSide effectO-acetylsalicylic acid
The invention discloses an anti-cancer medicinal aspirin platinum complex and a preparation method thereof. The method comprises the following steps of coordinating amine or heterocyclic amine on a platinum atom through a coordinated N atom and the coordination function of the platinum, introducing halogen or hydroxyl, carboxylate radical or substituted carboxylate radical through the coordination function, and oxidizing the platinum atom into tetravalent platinum, connecting aspirin molecular axially to form tetravalent platinum complex with one aspirin molecular single substitute or two aspirin molecular double substitutes axially. As the tetravalent state of the platinum is relatively inert, the toxic side effect on organs is small, and moreover, the uptake route of drug is changed, the anticancer activity of the drug is improved, the anti-tumor activity which is same to or even more excellent than that of cis-platinum is realized, and the killing function to the drug resistant cells is good. The preparation method provided by the invention is simple in structure, low in cost and suitable for industrial production.
Owner:UNIV OF SCI & TECH OF CHINA
Application of novel tyrosine kinase inhibitor-anlotinib in osteosarcoma
ActiveCN107970241AGrowth inhibitionInhibit transferOrganic active ingredientsInorganic active ingredientsLymphatic SpreadOsteosarcoma cell line
The invention relates to novel application of anlotinib and belongs to the technical field of medicine, namely effects of anlotinib in inhibition of growth and metastasis of osteosarcoma. The application disclosed by the invention has the advantages that the effect of the anlotinib for inhibiting growth and metastasis of osteosarcoma is discovered for the first time. The anlotinib is capable of obviously inhibiting the growth of osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, inducing cycle arrest of the osteosarcoma and inhibiting migration and invasiveness of the osteosarcoma cell lines.The anlotinib is first discovered to be capable of enhancing a killing effect of chemotherapeutic cis-platinum on osteosarcoma cells.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD
New use of anti-impaludism medicament hydroxyl chloroquine
InactiveCN101428025AMinimize or control damageClear anti-inflammatory activityOrganic active ingredientsAntineoplastic agentsHydroxychloroquineLysosome
The invention relates to the novel usage of an antimalarial medicine, in particular to the novel usage of hydroxychloroquine having sensitivity enhancing effect on various chemical anti-multiple myeloma medicaments. The novel usage is characterized in the application of hydroxychloroquine in treatment of multiple myeloma through chemotherapeutic medicaments. The hydroxychloroquine can obviously enhance the killing activity of chemotherapeutic medicines such as doxorubicine, epidoxorubicin, cis-platinum and mitoxantrone to multiple myeloma cells, and the killing activity thereof is realized by inhibiting the myeloma cell autophagy signals by hydroxychloroquine. Hydroxychloroquine can induce the quantity of the autophagy lysosomes of the multiple myeloma cells to be increased and the expression of the autophagy-associated albumen LC3-II to be increased.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Ruthenium complex as well as preparation method and use thereof
ActiveCN104650155ASmall side effectsIncrease fat solubilityOrganic active ingredientsRuthenium organic compoundsSide effectRuthenium
The invention relates to a ruthenium complex, the structural formula of which is shown in a formula I. Compared with cis-platinum, the ruthenium complex provided by the invention is small in toxic and side effects and is good in drug absorption, strong in anti-cancer activity, strong in ability of inducing tumor cell apoptosis and strong in ability of being bonded with DNA, and shows a good function in tumor treatment. The formula is shown in the description.
Owner:JIANGSU INST OF NUCLEAR MEDICINE
Medicine co-carried compound, micelle and preparation method of micelle
ActiveCN104784700AGood curative effectImprove stabilityOrganic active ingredientsHeavy metal active ingredientsSide effectCopolymer
The invention provides a medicine co-carried compound, micelle and a preparation method of micelle. The medicine co-carried compound is compounded by cis-platinum, adriamycin and a multi-arm copolymer, and the multi-arm copolymer has a structure of formula I (which is shown in the description). The medicine co-carried compound forms the micelle in an aqueous medium, a PEG block of the multi-arm copolymer is positioned on an external kernel of the micelle, a polyglutamic acid block or an aspartic acid block of the multi-arm copolymer is positioned on an internal kernel of the micelle, and the cis-platinum and the adriamycin are protected between the PEG block and the polyglutamic acid block or the aspartic acid block, so that the stability is good, and sudden release situation is avoided. Furthermore, the cis-platinum and a carboxyl of the multi-arm copolymer generate coordination, so that a cross linking function is achieved, and the stability of the micelle is improved; the adriamycin and the cis-platinum can quickly release and exert medicine functions around the tumor tissue or the tumor cell, so that the curative effect of the medicine is improved, and the toxic and side effects are reduced; based on experimental results, the medicine co-carried compound has an excellent tumor growth suppressing effect when being directly applied to treating rat melanoma lung metastatic cancer.
Owner:中科应化(长春)科技有限公司
Method of preparing nedaplatin with ultra-low content of silver
ActiveCN101012244ALow silver contentQuality improvementGroup 8/9/10/18 element organic compoundsPlatinumCis-platinum
The invention discloses a making method of naiad platinum with low-silver content, which comprises the following steps: reacting cis-platinum diiododiamide and silver nitrate with molar rate at 1: 2 for 3-8 h under 10-30 deg.c; filtering; adding halogenate MX [M is Na, K, Ca, Ba, NH4 or M is (CnH2n+1) 4N (n=1-4), X=Cl, Br, I] in the filtrate to remove trace silver; reacting for 0.5-1h under 10-30 deg.c; filtering; adding sodium glycolate in the solution; adjusting pH value to neutral to react for 3-10 h under 50-60 deg.c; decompressing; condensing; filtering; drying; obtaining the product; setting the molar rate of cis-platinum diiododiamide and sodium glycolate at 1: 1 and the molar rate of halogenate MX and silver nitrate at 0.1-0.01:1.
Owner:NANJING HAIRUN PHARM CO LTD
Red alga gracilariopsis lemaneiformis polysaccharide and preparation thereof, anti-tumor activity detection method and application
ActiveCN105542024AGood inhibitory effectSynergistic effect is obviousAlgae medical ingredientsAntineoplastic agentsLung cancerTumor cells
The invention discloses marine traditional Chinese medicine gracilariopsis lemaneiformis polysaccharide derived from red alga plant gracilariopsis lemaneiformis, discloses a synergistic effect of the gracilariopsis lemaneiformis polysaccharide serving as anti-tumor drugs, especially a synergist of cis-platinum for the first time, and further discloses an application of the gracilariopsis lemaneiformis polysaccharide to preparation of drugs or healthcare products or food for treating tumors. The gracilariopsis lemaneiformis polysaccharide can serve as a synergist of the anti-tumor drugs. The anti-tumor effect is achieved mainly by retraining growth and propagation of tumor cells, and the anti-tumor effect is achieved for gastric adenocarcinoma, lung cancer and carcinoma of the uterine cervix. The invention further discloses a preparation method of the gracilariopsis lemaneiformis polysaccharide and a detection method of the anti-tumor effect of the gracilariopsis lemaneiformis polysaccharide. A new way is provided for further utilization of gracilariopsis lemaneiformis serving as marine drug resources, and a new choice is provided for development of the anti-tumor drugs for treating or preventing tumors through the application of the gracilariopsis lemaneiformis polysaccharide to preparation of the anti-tumor drugs or anti-cancer healthcare products or food.
Owner:SHANGHAI JIAO TONG UNIV
Reduction responding covalent organic polymer and preparation method and application thereof
ActiveCN106344929AGood water solubilityGood biocompatibilityHeavy metal active ingredientsEnergy modified materialsSolubilityCancer cell
The invention provides a reduction responding covalent organic polymer and a preparation method and application thereof. The polymer provided by the invention is obtained by mixing and reacting carboxyl terminated polyethylene glycol, a compound with a structure shown in formula (I) and carboxylic cis-platinum prodrug, wherein the compound is obtained by respectively connecting 5,10,15,20-tetra(4-hydroxyphenyl) porphyrin with cis-platinum prodrug and polyethylene glycol, thus having good water solubility and biocompatibility; the obtained nano particles not only can produce singlet oxygen under laser radiation, but also can generate dissociation under the condition with high reducibility of cancer cells to release cis-platinum drugs, and has certain application in combined treatment of tumor; furthermore, the compound can also be directly used as a drug delivery system without a carrier, thus effectively avoiding use of additional carriers.
Owner:SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD
Application of emodin anthraquinone derivative in preparation of anti-hepatocellular carcinoma drugs
InactiveCN103356515AAvoid damageObvious cytotoxic effectOrganic active ingredientsAntineoplastic agentsApoptosisCancer cell proliferation
The invention provides application of an emodin anthraquinone derivative in preparation of anti-hepatocellular carcinoma drugs. The emodin anthraquinone derivative is a 1, 4-dimethyl-6, 8-dimethoxy-9, 10-anthraquinone. The derivative not only can well inhibit proliferation of hepatocellular carcinoma cells, induce their apoptosis, and also has very small toxicity to normal cells. The derivative can be used in conjunction with 5-FU, cis-platinum and other chemotherapy drugs to increase the sensitivity of the chemotherapy drugs, thus achieving the effect of inhibiting hepatocellular carcinoma cell growth. Therefore, the emodin anthraquinone derivative can be used for preparing anti-hepatocellular carcinoma drugs or adjuvant chemotherapy drugs.
Owner:SHANXI UNIV
Fat soluble dual-core cobalt (III) anti-tumor coordination compound and preparation method thereof
InactiveCN101885689ALow toxicityGood water solubilityOrganic active ingredientsHydrazone preparationCarboplatinDual core
The invention discloses a fat soluble dual-core cobalt (III) anti-tumor coordination compound and a preparation method thereof. The fat soluble dual-core cobalt (III) anti-tumor coordination compound belongs to lipophilic cobalt anti-tumor coordination compounds. The coordination compound of the invention has a chemical name of N,N'-bis(salicylidene)diamine cobalt (III) ([Co2(C14H12N2O2)3] for short), a molecular formula of C42H33Co2N6O6 and a molecular weight FW of 834.63, and is prepared by using CoAc2.4H2O as a raw material and by the steps of performing a quantitative reaction of the CoAc2.4H2O and ligand N,N'-bis(salicylidene)diamine in a solvent of dimethyl formamide and separating out products. The anti-tumor activity of the coordination compound is 1.6 times that of cis-platinum and 5 times that of carboplatin; an anti-tumor G150 value is 0.35mu g / mL; the activity is higher than those of the cis-platinum and carboplatin; and the coordination compound is low in toxicity and high in fat solubility and is used for clinical tumor treatment.
Owner:YUNNAN UNIV
Hyaluronic acid modified mitochondria target liposome and preparation method thereof
ActiveCN108743970AExtend cycle timeAvoid clearingOrganic active ingredientsPharmaceutical non-active ingredientsMedicineEtioplasts
The invention discloses hyaluronic acid modified mitochondria target liposome and a preparation method thereof. The mitochondria target liposome disclosed by the invention is prepared from drug carrying liposome and outer-layer modifying hyaluronic acid, wherein the drug loading liposome is liposome covered by hydrophobic drug and dequalinium chloride, and the hydrophobic drug is any one chosen from adriamycin, taxol, 10-hydroxycamptothecine, irinotecan or cis-platinum. The hyaluronic acid modified mitochondria target liposome disclosed by the invention has the beneficial effects that receptors are effectively targeted, uptake of tumor cells to liposome is improved, cell mitochondria is further targeted in the tumor cells, a function of damaging the mitochondria is achieved, tumor cell apoptosis is promoted, tumor cell growth is inhibited, and ability of overcoming multidrug resistance of the tumor cells is achieved.
Owner:SHANGHAI INST OF TECH
Antitumor agent and process for producing the same
InactiveUS20050208136A1Improving selective solid targeting capacityEliminate side effectsHeavy metal active ingredientsBiocideCancer cellPolyamine
The present invention relates to polymeric antitumor agent which is formed in polymeric micelle complex by intermolecular bonding or mutual interaction between styrene maleic acid copolymer (SMA) and low molecule antitumor agent which is anthracyclins drug such as pirarubicin, doxorubicin, epirbicin, daunorbicin, acralbicin, or alkaloid antitumor agent such as cis-platinum, and taxol These polymeric antitumor agents may improve specificity to cancer cells so that it improves antitumor effect, while it may not be concentrated at normal organ or tissue, so that adverse effect may be diminished. These polymeric antitumor agents may be prepared by dissolving SMA and low molecule antitumor agent in aqueous solution, then in the presence of aqueous soluble carbodiimide, amino acids, or polyamine, adjusting pH to form micelle complex and recovering polymer fraction.
Owner:MAEDA HIROSHI
Preparation method of RGD peptide and penetrating peptide R8 co-modified ergosterol and cis-platinum active drug-loading liposome
ActiveCN105796592AHigh encapsulation efficiencySmall toxicityOrganic active ingredientsHeavy metal active ingredientsSide effectRGD peptide
The invention discloses a preparation method of an RGD peptide and penetrating peptide R8 co-modified ergosterol and cis-platinum active drug-loading liposome. The method comprises the main steps of ergosterol liposome preparation, ammonium chloride gradient formation, drug loading and co-modification. The method is simple in technology and easy to carry out, and the encapsulation rate of a drug is high; ergosterol is adopted to partially replace cis-platinum to exert efficacy, an ergosterol and cis-platinum active drug-loading liposome is obtained, the effect of resisting a lung cancer is guaranteed, the toxic and side effects of the drug are significantly reduced, and damage to human bodies is small; meanwhile, the RGD peptide and the penetrating peptide R8 serve as target heads, the targeting property is good, and the drug exertion effect is good.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY
Lanthanum fullerenol and application in preparing medicaments for inhibiting tumor growth
ActiveCN101695502AReduce dosageLow toxicityHeavy metal active ingredientsCarbon active ingredientsHigh rateRare earth
The invention relates to lanthanum fullerenol and application in preparing medicaments for inhibiting tumor growth, in particular to lanthanum fullerenol nanoparticles with the general formula of M@C2m(OH)x and the application thereof in preparing medicaments for inhibiting tumor growth, wherein M is La rare earth metal, m is equal to 41 or 30, and X is equal to or larger than 10 and is less than 50; and because of the reorganization of adjacent hydroxyl groups, the quantity of O on C82 carbon cage is actually different from the quantity of H, and therefore, the general formula can be written in the form of M@C2mOXHY. Compared with cyclophosphamide, cis-platinum, taxol, and the like which are clinically and widely used, the lanthanum fullerenol M@C2m(OH)x or M@C2mOXHY has the advantages of low consumption and toxicity and high rate of tumor inhibition.
Owner:INST OF HIGH ENERGY PHYSICS CHINESE ACADEMY OF SCI
Gel preparation used for tumor in-situ treatment and preparation method
ActiveCN104721131ASustained in situ targeted therapyImprove anti-tumor effectOrganic active ingredientsHeavy metal active ingredientsGel preparationSide effect
The invention discloses gel preparation used for tumor in-situ treatment and a preparation method of the gel preparation. The gel preparation comprises taxol micella, cis-platinum, thermos-sensitive hydrogel and normal saline in the weight ratio of (100-250): (4-20): (2000-4000): (8000-6000), wherein the thermos-sensitive hydrogel is block polymer polyethylene glycol-polycaprolactone-polyethylene glycol. The gel preparation is used for local in-situ treatment of tumors, targeting of cis-platinum and taxol micella drugs can be improved, toxic and side effects are reduced, the difficulty of fixed-point application and in-situ local treatment of deep cancer tissue of cancer patients is solved and durable curative effect is achieved. In addition, the gel preparation has dual release effect, cis-platinum and taxol micella can be loaded at the same time, cell cycle-specific agent and non-specific agent are matched to achieve synergic effect and killing effect of the tumor tissue is improved.
Owner:THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
Application of brusatol as chemotherapeutic drug synergist
InactiveCN102106851AIncreased growth inhibitionIncrease lethalityOrganic active ingredientsAntineoplastic agentsCarboplatinCancer cell
The invention discloses a new application of brusatol serving as a chemotherapeutic drug synergist, which is combined with a chemotherapeutic drug when in use. The chemotherapeutic drug comprises cis-platinum, carboplatin, oxaliplatin, 5-fluorouracil, paclitaxel, adriamycin or adriamycin. The brusatol provided by the invention can be prepared into an oral preparation or a non-oral preparation accepted pharmaceutically. The beneficial effects of the brusatol applied in preparing the chemotherapeutic drug synergist are as follows: (1) the brusatol can be used in an Nrf2 path, and the killing effect of various chemotherapeutic drugs on the cancer cells can be enhanced; (2) the growth inhibition of low-dose cis-platinum on transplantable tumor of a naked mouse can be increased by the brusatol, thus having clinical application prospects; (3) the cis-platinum content in non-small cell lung cancer cell strains can be increased by the combined use of the brusatol and the cis-platinum; and (4)the toxicity is not discovered when the brusatol and the cis-platinum are together used in the cellular level and in the mouse test work concentration.
Owner:SHANDONG UNIV
Human intrahepatic duct cancer cell line and application thereof
InactiveCN104560878AAlgebraically clearNo cross contaminationMicrobiological testing/measurementMicroorganism based processesIntrahepatic CholangiocarcinomaIn vivo
The invention relates to a human intrahepatic duct cancer cell line and an application thereof. The human intrahepatic duct cancer cell line LICCF is established according to the invention, is clear and definite in algebra, does not have cross contamination, shows unique sensitivity to an inhibitor of a PI3K / mTOR passage and an inhibitor of an MEK1 / 2 passage, has high drug resistance to 5-FU, cis-platinum and FGFR inhibitors, and can be used for establishing in vivo and in vitro tumor drug experiment and drug resistance models, so that an experimental basis is provided for revealing a human intrahepatic duct cancer drug resistance mechanism, reversing the appearance of drug resistance, developing new anticancer drugs and screening human intrahepatic duct cancer related biological markers.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Compound with anti-cancer activity and preparation method and application thereof
ActiveCN106977403APrevent proliferationHigh anticancer activitySugar derivativesCarboxylic acid esters separation/purificationMedicineCis-platinum
The invention relates to a compound with the anti-cancer activity. The compound has a structure as shown in a general formula I. The compound can be extracted from cyclocarya paliurus by adopting a method which is simple, convenient and easy to operate. The compound provided by the invention can effectively inhibit proliferation of human breast cancer cells and hepatoma carcinoma cells; an effect of the compound is superior to that of a classical anti-cancer compound cis-platinum; the compound is excellent in anti-cancer activity, can be used for preparing medicines and health products, and has potential application value. The general formula I is shown in the description.
Owner:HUNAN UNIV OF CHINESE MEDICINE
Cis-platinum coordination compound and preparation method thereof
ActiveCN102604082AAvoid sudden releaseFacilitated releaseHeavy metal active ingredientsPharmaceutical non-active ingredientsSolubilityWater based
The invention provides a cis-platinum coordination compound which has a formula (I) structure or a formula (II) structure. The preparation method of the cis-platinum coordination compound is as follows: cis-platinum and a block copolymer with a formula (III) or a formula (IV) are subjected to coordination action in a water-based medium so as to generate the cis-platinum coordination compound. The cis-platinum coordination compound has good dissolubility and good biocompatibility and is degradable. In the water-based medium, the cis-platinum is protected by a poly (Gamma-propinyl-L-glutamate-g-dimercaptosuccinic acid) block and a polyethylene glycol block, so that the cis-platinum coordination compound has good stability. In addition, carboxyl contained in the cis-platinum coordination compound has PH-value sensibility, and in a lower PH-value environment, the carboxyl trends to be deprotonated, the releasing of the medicaments is promoted, and the curative effects of the medicaments are improved.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
RGD peptide and penetrating peptide R8 co-modified ergosterol and cis-platinum active drug-loading liposome
ActiveCN105796593ASmall toxicityReduce harmHeavy metal active ingredientsOrganic active ingredientsCyclic peptideWater baths
The invention discloses an RGD peptide and penetrating peptide R8 co-modified ergosterol and cis-platinum active drug-loading liposome which is prepared through incubation of an ergosterol and cis-platinum active drug-loading liposome, RGD cyclic peptide and penetrating peptide R8 in a water bath. The ergosterol and cis-platinum active drug-loading liposome is prepared from an ergosterol liposome and a cis-platinum solution, the ergosterol liposome is prepared from 8 wt%-15 wt% of ergosterol and 85%-92% of liposomes, and the liposomes are composed of lecithin and cholesterol. According to the RGD peptide and penetrating peptide R8 co-modified ergosterol and cis-platinum active drug-loading liposome, ergosterol is adopted to partially replace cis-platinum to exert efficacy, the effect of resisting a lung cancer is guaranteed, the toxic and side effects of a drug are significantly reduced, and damage to human bodies is small; meanwhile, the RGD peptide and the penetrating peptide R8 serve as target heads, the targeting property is good, and the drug exertion effect is good.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY
Application of dioscin in preparing drug-resistant osteosarcoma medicine
ActiveCN108295085APrevent proliferationInhibit apoptosisOrganic active ingredientsSkeletal disorderOsteosarcoma cell lineCis-platinum
The invention discloses application of dioscin in preparing a drug-resistant osteosarcoma medicine. Drug-resistant osteosarcoma refers to an osteosarcoma cell line which has drug resistance to commonanti-tumor medicines, particularly U2OS tumor cells with drug resistance to methotrexate, doxorubicin and cis-platinum. Moreover, as a natural plant extract medicine, dioscin has wide application prospects in the field of anti-tumor medicine treatment.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Aprepitant intravenous injection emulsion as well as preparation method and application thereof
PendingCN109364023AImprove liquidityNo hanging phenomenonOrganic active ingredientsDigestive systemHigh dosesMarketed products
The invention relates to aprepitant intravenous injection emulsion as well as a preparation method and an application thereof, and belongs to the technical field of pharmaceutics. The aprepitant intravenous injection emulsion is prepared from components in percentage by mass as follows: 0.05%-3% of aprepitant, 5%-30% of an oil phase solvent, 1.2%-18% of an emulsifier, 0.03%-0.6% of a stabilizer and 1%-5% of an isoosmotic adjusting agent, the injection emulsion further contains a pH regulating agent and the balance of water for injection, and pH value of the injection emulsion is 5.5-8.0. The aprepitant intravenous injection emulsion contains no low-carbon chain alcohol such as ethanol and the like, meanwhile, the quality requirement for a marketed product can be met by technological innovation and adjustment, and clinical use safety of the aprepitant intravenous injection emulsion is greatly improved; direct intravenous injection is utilized during clinical using, and dilution is not needed; the aprepitant intravenous injection emulsion can be used for treating acute and tardive nausea and vomiting caused by high-dose cis-platinum combined high-dose sensitizing cancer chemotherapy,and nausea and vomiting in early stage and middle stage of tumor chemotherapy are reduced.
Owner:GUANGZHOU HANFANG PHARMA
Application of 18 beta-glycyrrhetinic acid (or salt) for serving as auxiliary treating drug capable of easing acute kidney injury caused by chemotherapeutic drug, namely cis-platinum
InactiveCN106539803APrevention and mitigation of acute kidney injuryOrganic active ingredientsUrinary disorderUrea nitrogenCreatinine rise
The invention belongs to the field of pharmacotherapeutics, and particularly relates to application of 18 beta-glycyrrhetinic acid (or salt) for serving as an auxiliary treating drug capable of easing acute kidney injury caused by a chemotherapeutic drug, namely cis-platinum, wherein the 18 beta-glycyrrhetinic acid (or salt) is one of the main components of liquorice. The cis-platinum serves as a commonly-used chemotherapy drug, and clinical application thereof is restricted by kidney toxicity thereof. The levels of creatinine and urea nitrogen in the acute kidney injury induced by the cis-platinum can be inhibited by the18 beta-glycyrrhetinic acid, expression of KIM-1 injured protein is lowered, and apoptosis of renal tubular epithelial cells caused by the cis-platinum is inhibited. According to the application of the 18 beta-glycyrrhetinic acid (or salt) for serving as the auxiliary treating drug capable of easing the acute kidney injury caused by the chemotherapeutic drug, namely the cis-platinum, the effect that the 18 beta-glycyrrhetinic acid has a protecting effect on the acute kidney injury caused by the cis-platinum is discovered for the first time, a mechanism of the 18 beta-glycyrrhetinic acid is related to inhibiting of apoptosis of the renal tubular epithelial cells, and a novel potential drug is provided for Chinese medicine anti-cancer adjuvant therapy.
Owner:ANHUI MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com